Mitochondrial Health Foundations

Quick reference — the 5-part anatomy → intervention map

Sub-system	What it does	What breaks it	What fixes it
Outer membrane (the “front door”)	Lets fuel, nutrients, and signals into the cell’s power plant	Chronic inflammation, insulin resistance, oxidative stiffening	Antioxidants (colorful plants), omega-3 (EPA/DHA), phosphatidylcholine
Inner membrane / cristae (the “engine bay”)	Folded surface where the ATP-making machinery sits — more folds = more energy output	Aging, sedentary life, oxidative damage flattens the folds	Exercise (outperforms every supplement here), SS-31 (Elamipretide) (binds cardiolipin, stabilizes the folds)
Electron transport chain (the “5-station assembly line”)	Moves electrons through 5 complexes → builds a proton gradient → spins the ATP turbine	Complex I damage from aging + inflammation, statin-driven CoQ10 depletion	CoQ10 (electron shuttle), riboflavin (complex I/II cofactor), Methylene Blue — the alternative-electron-carrier mitochondrial adjunct (and the SSRI hard line you need to know about) (alternative electron carrier — bypasses damaged complexes)
Matrix (the “soup in the middle”)	Houses the Krebs cycle + mitochondrial DNA; loads NADH/FADH₂ delivery trucks with electrons	Depleted NAD pool, oxidative damage to mtDNA	NAD+ / NMN supplementation (matrix substrate); Glutathione (mtDNA ROS buffer)
Mitophagy + biogenesis (the “demolition crew + construction crew”)	Recycles damaged mitochondria; builds new ones via the PGC1-α master switch	Sedentary life + metabolic dysfunction slow recycling; broken mitos breed more broken mitos	Urolithin A (mitophagy support), exercise + fasting + cold exposure (biogenesis via PGC1-α), MOTS-c (PGC1-α activator + AMPK-driven biogenesis)

The OHM bottom line: there is no single best mitochondrial supplement. There are interventions that target different parts of the machine. Knowing which sub-system is broken — and which lever fixes that specific sub-system — turns “I’m tired and I bought $400 of supplements” into a coherent protocol.

What this article is for

The mitochondrial-health space is one of the most confusing corners of the longevity and wellness market. There are dozens of “mitochondrial support” supplements on the shelf, each claiming to do something to your power plants. Most of them are biologically real — they DO work on the mitochondrion — but they target completely different sub-systems. Stacking them blindly is how customers end up with a $300/month supplement bill and the same exhaustion they started with.

This article is the upstream framework that the per-peptide and per-supplement wiki articles connect into. It exists because OHM customers asking “should I take MOTS-c or NAD+?” are asking the wrong question. The right question is “which sub-system of my mitochondria is failing?” — and the answer points you at the right lever. MOTS-c and NAD+ aren’t competitors; they target different parts of the system and stack rather than overlap.

The 5-part anatomy mapping below comes most cleanly from Dr. Ashley Froese’s 2026-06-28 mitochondria explainer, but the underlying biology is textbook cell biology + 60 years of mitochondrial bioenergetics literature — every claim here is anchored in primary sources, not in any single video.

How the mitochondrion actually works (the 5-part anatomy)

Picture a bean shape with two walls, a smooth outer wall and a heavily folded inner wall. Between the walls sits the inter-membrane space — call it the “loading dock.” Inside the inner wall is the matrix — the “soup in the middle” where most of the chemistry happens. And running through and around the whole thing is the recycling-and-rebuilding system that constantly replaces damaged units with new ones. Five sub-systems, each with a specific job. [ESTABLISHED — undergraduate cell biology; full mechanism review in Murphy 2009 Biochem J 417(1):1-13, DOI 10.1042/BJ20081386].

1. The outer membrane — the front door

The outer mitochondrial membrane is porous and fluid. It’s how fuel, oxygen, and signaling molecules get into the cell’s power plant. When chronic inflammation, insulin resistance, or oxidative damage build up over years, this outer membrane stiffens — the gates rust up, fuel and signals have a harder time getting through, and the cell starts running on a half-charged battery even when the inside of the mitochondrion is fine. This is the “signal interference” failure mode: you’re not low on energy because the engine is broken, you’re low on energy because messages can’t get to the engine.

The membrane is made primarily of phospholipids — fatty molecules arranged in a bilayer. In mammalian mitochondrial membranes, the lipid composition by mass is approximately phosphatidylcholine ~40%, phosphatidylethanolamine ~35%, cardiolipin ~20%, phosphatidylinositol ~5% [ESTABLISHED — Horvath & Daum 2013, Prog Lipid Res 52(4):590-614, PMID 24007978]. Phosphatidylcholine is the dominant building block (though not overwhelmingly so — phosphatidylethanolamine is close behind, and cardiolipin is the signature lipid of the inner membrane). When the diet doesn’t supply enough of these phospholipid precursors, or when oxidative damage exceeds the body’s repair capacity, the membrane composition shifts away from healthy proportions and the membrane fluidity changes.

2. The inner membrane and cristae — the engine bay

The inner mitochondrial membrane is the most interesting structural feature in the whole organelle. It’s not smooth — it’s folded over and over again into accordion-like pleats called cristae. The reason: more folds means more surface area, and the entire ATP-making machinery (the electron transport chain plus ATP synthase) is embedded into this folded membrane. More cristae folds = more room for ATP engines = more energy output [ESTABLISHED — exercise physiology + bioenergetics literature].

In healthy, metabolically active mitochondria, cristae are deep, tightly organized, and beautifully folded. In aged, stressed, or damaged mitochondria, the folds flatten out — the accordion loses its shape, and the cell can’t make as much ATP per mitochondrion regardless of fuel input. This is one of the structural signatures of mitochondrial aging that shows up clearly under electron microscopy.

The unique lipid here is cardiolipin, which makes up ~20% of inner-membrane phospholipid mass but is found almost nowhere else in the cell. Cardiolipin is what holds the cristae folds in their tight architecture and what stabilizes the electron transport chain complexes. This is the structural lever that SS-31 (Elamipretide) (elamipretide) targets — SS-31 binds cardiolipin directly and stabilizes the inner-membrane architecture, which is the only FDA-approved peptide mechanism in the mitochondrial cluster (approved in 2025 for Barth syndrome — see the SS-31 article for the regulatory + mechanism detail).

3. The electron transport chain — the 5-station assembly line

The electron transport chain (ETC) is the machinery embedded in the cristae folds, where food gets converted to ATP. It’s a five-station assembly line, technically called complexes I, II, III, IV, and V. The process:

1. Food gets broken down (in the matrix — section 4 below) into electron-delivery molecules called NADH and FADH₂.
2. NADH drops electrons off at complex I; FADH₂ drops them at complex II.
3. The electrons get passed down the line through complexes III and IV.
4. As electrons move, protons (hydrogen atoms minus their electron) get pumped from the matrix across the inner membrane into the inter-membrane space.
5. This creates a charge and concentration gradient — stored potential energy, like water pumped uphill into a reservoir.
6. The protons rush back through complex V (ATP synthase), which spins like a turbine and forges ATP — the energy currency the rest of the cell runs on.

Complex I is the most damage-prone station. Aging, chronic inflammation, and certain drug exposures slow it down — and when complex I lags, the whole assembly line backs up [ESTABLISHED — Murphy 2009 PMID 19061483 mechanism review]. This is where most of the targeted supplements act:

• CoQ10 (ubiquinone) is the electron shuttle that moves electrons between complex I/II and complex III. It’s the traffic cop between stations. Endogenous CoQ10 synthesis happens in the body via the HMG-CoA reductase pathway — the same pathway that produces cholesterol. Statins inhibit HMG-CoA reductase to lower cholesterol, but they cut off CoQ10 synthesis at the same upstream step. Statin users frequently run a low-grade CoQ10 deficit that shows up as fatigue, exercise intolerance, or muscle aches; CoQ10 supplementation is the mitigation — it doesn’t undo the statin’s job, it refills what the statin depleted. The clinical evidence base is strongest in chronic heart failure: the Q-SYMBIO trial (420 patients, CoQ10 100 mg three times daily, 2-year follow-up) showed a 50% reduction in the composite endpoint of cardiovascular death + heart failure hospitalization + mechanical circulatory support + transplant (HR 0.50, 95% CI 0.32–0.80, p=0.005). This is one of the cleanest RCT signals in the mitochondrial-supplement literature.

• Riboflavin (vitamin B2) is a precursor to the FAD cofactor at complex I and complex II. Riboflavin deficiency is the cleanest single-vitamin cause of mitochondrial dysfunction; supplementation supports complex I/II function in users who are deficient or marginal.

• Methylene Blue — the alternative-electron-carrier mitochondrial adjunct (and the SSRI hard line you need to know about) is the unusual one. At low doses, methylene blue cycles between oxidized (MB) and reduced (MBH₂) states, acting as an alternative electron carrier that accepts electrons from NADH and delivers them directly to cytochrome c, bypassing complexes I and III if they’re damaged or inhibited [ESTABLISHED mechanism — Yang et al. 2016 Prog Neurobiol PMC4871783; Tucker et al. 2018 Mol Neurobiol PMID 28840449]. The biology is real: methylene blue functionally reroutes traffic around damaged complexes. The dose-response is biphasic — low doses (~0.5–4 mg/kg) drive the electron-shuttle effect; high doses paradoxically generate ROS rather than reducing them. The major safety constraint is the serotonin-syndrome interaction with SSRIs, SNRIs, MAOIs, and certain other serotonergic drugs, which carries an FDA Safety Communication. The full safety + dosing detail lives in wiki/methylene-blue.md.

4. The matrix — the soup in the middle

The matrix is the inside of the mitochondrion — the protein-and-enzyme soup enclosed by the inner membrane. Three important things happen here:

(a) The Krebs cycle (citric acid cycle, TCA cycle). This is where carbon fuel (from carbohydrate, fat, and protein breakdown) gets oxidized and the electrons get loaded onto NADH and FADH₂ delivery molecules. The NADH and FADH₂ then carry those electrons to the electron transport chain on the inner membrane. The Krebs cycle is the source of the electron flow that drives ATP production.

(b) The NAD pool. NAD+ (oxidized) gets reduced to NADH (which carries electrons) during the Krebs cycle, then NADH dumps electrons at complex I and converts back to NAD+. The total NAD pool (NAD+ plus NADH) sets the upper limit on how fast the Krebs cycle can run. The NAD pool declines with age, with chronic inflammation, with poor sleep, and with metabolic dysfunction — and a depleted NAD pool means a bottlenecked Krebs cycle, which means fewer NADH delivery trucks to the ETC, which means lower ATP output. This is the rationale for NAD+ / NMN supplementation: refill the matrix substrate pool so the Krebs cycle can run at capacity again. The mechanism is well-established; the customer-decision detail (precursor choice, oral vs SubQ bioavailability, dosing) lives in the NAD article.

© Mitochondrial DNA (mtDNA). Mitochondria contain their own DNA — separate from nuclear DNA — that codes for some of the proteins of the electron transport chain. Because mtDNA sits in the matrix where ROS production happens, it’s particularly vulnerable to oxidative damage. Damaged mtDNA leads to defective ETC proteins, which leads to more ROS, which leads to more mtDNA damage. This is one of the vicious cycles that drive mitochondrial aging. The fix is upstream (reduce ROS production via good ETC function + antioxidant defense) rather than direct (you can’t supplement mtDNA).

5. Mitophagy and biogenesis — the demolition crew and the construction crew

Mitochondria aren’t permanent. Healthy cells constantly destroy damaged mitochondria and build new ones — a turnover process that keeps the mitochondrial population fresh and functional.

Mitophagy is the demolition side. Cells identify damaged mitochondria (via specific tags that get placed on dysfunctional units), break them apart, and recycle the useful pieces. Think of it as controlled demolition. As people age, become sedentary, or develop metabolic dysfunction, the mitophagy process slows down — and broken mitochondria accumulate. Worse: dysfunctional mitochondria tend to fission (split) and produce more dysfunctional mitochondria, so the problem compounds. A factory full of malfunctioning equipment that doesn’t get cleaned out keeps making more malfunctioning equipment.

Urolithin A is the most-discussed nutritional intervention for mitophagy. It’s a compound the gut microbiome produces from ellagitannins (found in pomegranates, walnuts, and some berries). Not everyone is an efficient converter — roughly 40% of people have the right gut bacteria to produce useful amounts of urolithin A from dietary ellagitannins; the rest need direct urolithin A supplementation. Urolithin A activates mitophagy signaling, helping the cell identify and clear damaged mitochondria.

Biogenesis is the construction side. The master regulator of mitochondrial biogenesis is a transcriptional coactivator called PGC1-α (peroxisome proliferator-activated receptor gamma coactivator 1-alpha). When PGC1-α gets activated, downstream signaling tells the cell to build new mitochondria — more power plants, more cristae, more ATP capacity. Multiple unrelated interventions converge on PGC1-α as their common downstream effector [ESTABLISHED — extensive PGC1-α biology, foundational work by Lin & Spiegelman group]:

• Exercise (the strongest activator known)
• Fasting / caloric restriction
• Cold exposure
• NAD+ replenishment (NAD+ is a substrate for SIRT1, which deacetylates and activates PGC1-α)
• MOTS-c (via AMPK → SIRT1 → PGC1-α pathway — the molecular reason MOTS-c is called an “exercise mimetic”)
• Certain mitochondrial-targeted polyphenols (resveratrol, urolithin A indirectly)

These are not redundant levers — they’re synergistic, because they reach the same downstream signal through different upstream routes. Exercise + fasting + cold + MOTS-c stacks rather than competes, because the signal converges at PGC1-α and downstream biogenesis output reflects how strongly the master switch was activated and for how long.

The OHM editorial spine — foundation first, peptides amplify

Here is the single most important takeaway from the mitochondrial-health framework, and the reason OHM’s voice on this topic is different from the typical longevity-supplement marketing:

Exercise is the single most powerful intervention for mitochondrial structure — and it outperforms every supplement on the shelf at the cristae-remodeling and biogenesis layer.

This isn’t a polite gesture toward “diet and exercise are important.” It’s a load-bearing claim about mechanism: consistent exercise (endurance training in particular, with mounting evidence for high-intensity interval work) is the strongest known activator of PGC1-α, the master switch for biogenesis. It also drives cristae remodeling — the cristae of trained skeletal muscle are denser and more organized than the cristae of untrained muscle. No supplement comes close to exercise at this specific layer.

Why does this matter for OHM customers? Because the marketing for mitochondrial supplements often implies you can buy your way to good mitochondrial function. You can’t. You can buy a coherent supplemental and peptide layer that amplifies the foundation you’ve already built, but if there’s no foundation underneath — sedentary, sleep-deprived, poor diet — then MOTS-c isn’t ramping up a healthy system, it’s adding demand to a misfiring one. The clinical signature of running the peptide layer on a missing foundation is the customer who reports “I tried MOTS-c and felt nothing” or “I felt worse.” The peptide is doing what it’s supposed to do — amplifying — and there’s nothing healthy underneath to amplify.

The right sequence:

1. Foundation first. Resistance training + endurance training (the structural lever). Sleep (the recovery + glymphatic-clearance lever). Clean enough diet to supply membrane phospholipid precursors and to avoid driving inflammation. Sun exposure for circadian alignment.
2. Adjunct supplements. CoQ10 if on statins (non-negotiable). Omega-3 + phosphatidylcholine for membrane composition. NMN or another NAD+ precursor for matrix support. Urolithin A for mitophagy, especially in the older or sedentary user who isn’t generating enough biogenesis signaling from lifestyle alone.
3. Peptide layer. This is the amplification stage. MOTS-c for biogenesis + AMPK-driven metabolic flexibility. SS-31 (Elamipretide) for cristae structural stabilization (the only FDA-approved mitochondrial peptide). NAD+ (injectable) for matrix support when oral precursors aren’t enough.

This sequence isn’t OHM being conservative. It’s OHM being honest about what the biology will and won’t do. The empowering reframe: you can actually fix this — you just need to fix it in the right order.

The peptide layer — cross-link map

Each entry below is a one-paragraph orientation. Click through for the deep dive (mechanism, dosing, vendor mapping, safety profile).

• MOTS-c — the headliner of the mitochondrial-peptide class. A 16-amino-acid mitochondrial-derived peptide that activates AMPK, drives the SIRT1/PGC1-α biogenesis pathway, and behaves as an exercise mimetic. The biogenesis-layer peptide. Alyve in-catalog SKU. Strong animal evidence base, growing human observational data, dedicated human RCTs still being built. Pairs with: SS-31 (foundation), NAD+ (matrix support), the lifestyle biogenesis levers (exercise + fasting + cold).

• SS-31 (Elamipretide) — the cristae-stabilization peptide. Binds cardiolipin directly in the inner mitochondrial membrane, holds the cristae folds in their tight architecture, reduces electron leakage at the source. The only FDA-approved peptide in the mitochondrial cluster (2025 approval for Barth syndrome, brand name Forzinity). Roadmap candidate at Alyve (not in the launch catalog yet). The “hardware-fix” peptide — pair with MOTS-c (the “software” — the biogenesis signal) for the cleanest sequencing.

• NAD+ — not a peptide in the strict sense; it’s the matrix substrate that feeds the entire Krebs cycle → ETC pipeline. Alyve in-catalog (NAD+ injectable). The matrix-layer intervention. Pairs with: MOTS-c (provides the antioxidant + DNA-repair substrate for the increased metabolic throughput MOTS-c drives); SIRT1-coupled compounds.

• 5-Amino-1MQ — NNMT inhibitor, prevents the salvage-pathway drain on NAD+ methyl groups. Adjunct to NAD+ supplementation; the “stop wasting what you’re refilling” lever.

• Glutathione — the master antioxidant; downstream buffer for ROS produced as a byproduct of ETC operation. The protective layer for high-throughput mitochondrial activity (MOTS-c stacks, intense training blocks). Foundation-tier supplement when stacking active mitochondrial peptides.

• Epithalon — pineal-axis / telomerase peptide. Crosses with mitochondrial-aging biology at the longevity-stack layer rather than the direct mechanism layer; relevant for the deeper longevity sequencing question rather than the immediate fatigue/energy question.

• Humanin & ARA-290 — the endogenous protection cluster — other mitochondrial-derived peptides (humanin) and tissue-protective fragments (ARA-290). Roadmap-tier; less customer-facing momentum than MOTS-c and SS-31. Worth knowing the cluster exists.

The adjunct-supplement layer

The 2026-06-18 KB scope expansion explicitly brought peptide-adjunct supplements into scope, because Pep (OHM’s chatbot) and any coaching surface needs to be able to talk about the full stack, not just the injectable. The mitochondrial cluster has the most fleshed-out adjunct layer in the KB; here are the load-bearing entries:

• CoQ10 (ubiquinone / ubiquinol). ETC electron shuttle, complex I→complex III. Non-negotiable for statin users — the iatrogenic CoQ10 deficit is real and the mitigation is cheap. Best human RCT signal in the mitochondrial-supplement literature: Q-SYMBIO chronic heart failure trial (Mortensen 2014 PMID 25282031). Ubiquinol (the reduced form) has somewhat better oral bioavailability than ubiquinone in older or oxidatively-stressed users; ubiquinone is fine for younger users.

• NMN (nicotinamide mononucleotide). Oral NAD+ precursor; supports matrix NAD pool. Reasonable foundation supplement; the more potent intervention for users who don’t respond is direct NAD+ injection (see the NAD+ article for the bioavailability hierarchy).

• Urolithin A. Mitophagy support; particularly relevant for older / sedentary users whose endogenous mitophagy signaling has slowed. Direct supplementation bypasses the gut-microbiome conversion bottleneck (~40% of people are efficient converters from dietary ellagitannins; the rest aren’t). Mitopure is the commercially-available direct urolithin A product; dietary sources (pomegranate, walnut, certain berries) work for the ~40% who convert efficiently.

• Phosphatidylcholine. The dominant phospholipid in mitochondrial membranes (~40% of total mass). Sunflower lecithin or soy lecithin are the standard dietary sources; the supplement is useful for users with poor dietary fat intake or with suspected membrane-composition issues. Mechanistically supports outer-membrane fluidity + integrity.

• Omega-3 (EPA + DHA). Membrane fluidity + anti-inflammation. Reduces the inflammatory load that stiffens the outer mitochondrial membrane. A foundation supplement that crosses multiple OHM branches (cardiovascular, brain, mitochondrial, joint).

• Riboflavin (vitamin B2). Complex I/II cofactor (FAD precursor). Deficiency is the cleanest single-vitamin cause of ETC dysfunction; correction is dramatic in deficient users, marginal in replete users.

• Methylene Blue — the alternative-electron-carrier mitochondrial adjunct (and the SSRI hard line you need to know about) (full article exists). ETC bypass for damaged complexes. The serotonin-syndrome interaction with SSRIs / SNRIs / MAOIs is the major safety constraint — see the methylene blue article for the full interaction profile and dosing. Low-dose only; dose-response is biphasic.

• Magnesium. Required cofactor for ATP synthase (the complex V turbine). Most adults are subclinically magnesium-deficient. Glycinate is the preferred form for systemic effect; threonate for the brain-mitochondrial application.

Per-condition application — "where should I start?"

The 5-part anatomy → intervention map is most useful when you know which sub-system is most likely failing. A rough decision aid for OHM customers presenting with the most common complaints:

• Chronic fatigue, slow recovery, brain fog without obvious cause. Start at the matrix + ETC layers. CoQ10 (especially if on statins), NMN or NAD+ injectable, riboflavin if dietary intake is poor. Add MOTS-c once the foundation is in place if the fatigue is the structural-energy kind rather than the sleep-deprivation kind.

• Statin-related fatigue or muscle aches. Start with CoQ10 (ubiquinol form preferred). The mitigation is well-documented and cheap. If symptoms persist, add the rest of the matrix-layer support (NMN, riboflavin) and talk to the prescribing physician about whether the statin dose is calibrated correctly.

• Metabolic syndrome / insulin resistance / pre-diabetes. This is a whole-mitochondrial problem (outer-membrane stiffening from inflammation, ETC slowdown, matrix substrate depletion). Foundation first — resistance training is the most powerful insulin-sensitivity lever known. Then the matrix-layer support (NAD+/NMN). MOTS-c is in the conversation here because of its AMPK + GLUT4 mechanism, but it’s the amplification layer, not the foundation.

• Cognitive fatigue or early cognitive decline. Cross-references several layers: mtDNA + ROS (oxidative damage in neurons), ETC + cristae structure (neurons are extraordinarily energy-demanding), and biogenesis (the brain has its own mitochondrial-renewal mechanisms). Methylene Blue — the alternative-electron-carrier mitochondrial adjunct (and the SSRI hard line you need to know about) has the strongest mechanism story specifically for cognitive applications at low dose; MOTS-c crosses the blood-brain barrier and supports BDNF (per the MOTS-c animal literature); the lifestyle layer (sleep, exercise, omega-3) does heavy work here.

• Post-exercise recovery is slower than it used to be. Biogenesis + mitophagy layer. Urolithin A, MOTS-c in 8-week cycles, NAD+. And honest acknowledgment that part of slower recovery is age-related changes that no peptide fully reverses — the goal is “best version of the current biology,” not “biology of a 25-year-old.”

• General longevity / preventive optimization. This is the stacking question. The OHM house framing: lifestyle foundation (always-on) + adjunct supplements (always-on with seasonal adjustments) + peptide cycles (rotated through the year — see the MOTS-c cycling discussion for the standard 8-12 week on-cycle, multi-month off pattern). SS-31 (Elamipretide) is the exception — because it has no receptor and binds cardiolipin directly, year-round low-dose use is reasonable.

ROS — the "sparks flying off the machinery" framing

One nuance worth understanding before loading up on antioxidant supplements: the goal is regulated ROS, not eliminated ROS.

About 1–2% of the oxygen that gets pushed through the ETC leaks out as reactive oxygen species — primarily superoxide (O₂⁻), produced mostly at complex I and complex III under specific operating conditions [ESTABLISHED — Murphy 2009 Biochem J 417(1):1-13, the canonical recent treatment; original estimates ranged 0.1–2% depending on substrate and uncoupling state]. A few sparks is normal and necessary — the body uses sub-toxic ROS for redox signaling, hormetic adaptation, and pathogen defense. This is called mitohormesis: small, controlled ROS exposure (like the brief ROS spike during exercise) triggers adaptive responses that make the mitochondria more resilient over time.

The problem isn’t ROS per se; it’s unregulated or chronically elevated ROS — what happens when chronic inflammation, poor sleep, bad diet, sedentary behavior, or damaged ETC components keep the sparks flying constantly. Then ROS damages mtDNA, oxidizes membrane lipids, and accelerates the vicious cycle of mitochondrial dysfunction.

The practical implication: load up on antioxidants is the wrong frame. The right frame is support the body’s endogenous antioxidant systems (Glutathione precursors like NAC and glycine; selenium for glutathione peroxidase; vitamin E + C for the lipid-soluble + water-soluble compartments) and reduce the upstream ROS-driving inputs (sleep, training intelligently rather than excessively, inflammation control). High-dose pulse-antioxidant supplementation can actually blunt the hormetic exercise response in some studies — another example of “more is not better” in the mitochondrial space.

What this article does NOT replace

• The per-peptide deep dives. The MOTS-c, SS-31, NAD+, glutathione, methylene blue, 5-Amino-1MQ, epithalon, and humanin-ARA-290 articles each go far deeper into mechanism, dosing, vendor mapping, regulatory status, and safety than this foundation article does. This article is the framework; those are the levers.

• A specific protocol. “How much CoQ10 should I take, and when?” is answered in wiki/coq10.md once it exists; this article points you at the framework that says CoQ10 is the right tool for the statin-user ETC-bypass problem but does not prescribe the dose.

• The lifestyle layer. Foundation-tier interventions (sleep, exercise programming, dietary frameworks, sun exposure, circadian alignment, stress management) live in their own OHM branches once those branches are populated. The peptides KB notes the foundation is mandatory; the foundation’s own how-to lives where it belongs.

Honest limits

A few places where the framework above runs ahead of the empirical evidence:

• The “exercise dominates supplements” claim is well-supported for cristae remodeling and biogenesis, but the comparative magnitude vs. the best modern interventions (high-dose NAD+ injectables, SS-31, MOTS-c in animal models) hasn’t been head-to-head studied in humans. The directional claim is solid; the exact relative effect sizes aren’t.

• The 5-part anatomy → intervention map is a teaching scaffold, not a diagnostic instrument. Real human mitochondrial dysfunction is rarely confined to one sub-system — it’s usually distributed, and the highest-value lever is whichever one happens to be the rate-limiting step in that individual. The matrix-first / ETC-first / biogenesis-first / mitophagy-first framing in the per-condition section above is a starting heuristic, not a diagnostic test.

• Most of the foundational discoveries (PGC1-α as master switch, the 5-complex ETC architecture, the cardiolipin-cristae structural relationship) are well-established in textbook biology. The clinical translation of how to optimally manipulate them is still being worked out, especially the peptide-layer interventions. Strong mechanism + modest human RCT base is the honest tier for most of the peptide layer; clean mechanism + strong RCT base (Q-SYMBIO CoQ10 in heart failure) is rare in this space.

• Anyone with active mitochondrial disease, primary mitochondrial disorders, or specific genetic conditions affecting the ETC should be working with a clinician who understands the molecular biology rather than self-directing from a foundation article. The framework above is for general optimization in adults with normal-baseline mitochondrial biology, not for replacing clinical care in mitochondrial-disease populations.

Sources

Primary scientific anchors:

• Holloszy JO. Biochemical adaptations in muscle: Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle. J Biol Chem 1967;242(9):2278-2282. The foundational paper establishing exercise-induced mitochondrial biogenesis. Pre-PubMed era, no indexing; canonical citation across exercise physiology.
• Memme JM, Erlich AT, Phukan G, Hood DA. Exercise and mitochondrial health. J Physiol 2021;599(3):803-817. DOI 10.1113/JP278853. The current synthesis review of exercise → mitochondrial quality control + biogenesis + cristae remodeling.
• Horvath SE, Daum G. Lipids of mitochondria. Prog Lipid Res 2013;52(4):590-614. PMID 24007978. The canonical lipidomics reference for mitochondrial membrane composition.
• Murphy MP. How mitochondria produce reactive oxygen species. Biochem J 2009;417(1):1-13. PMID 19061483. The mechanism reference for the 1-2% O₂-leak / superoxide-as-proximal-ROS framing.
• Mortensen SA, Rosenfeldt F, Kumar A, et al. The effect of coenzyme Q10 on morbidity and mortality in chronic heart failure: results from Q-SYMBIO: a randomized double-blind trial. JACC Heart Fail 2014;2(6):641-649. PMID 25282031. The RCT anchor for CoQ10 efficacy.
• Andreux PA, Blanco-Bose W, Ryu D, et al. The mitophagy activator urolithin A is safe and induces a molecular signature of improved mitochondrial and cellular health in humans. Nat Metab 2019;1:595-603. DOI 10.1038/s42255-019-0073-4. First-in-human urolithin A clinical trial.
• Yang SH, Li W, Sumien N, Forster M, Simpkins JW, Liu R. Alternative mitochondrial electron transfer for the treatment of neurodegenerative diseases and cancers: Methylene blue connects the dots. Prog Neurobiol 2017;157:273-291. PMC4871783. The methylene blue alternative-electron-carrier mechanism reference.
• Tucker D, Lu Y, Zhang Q. From mitochondrial function to neuroprotection — an emerging role for methylene blue. Mol Neurobiol 2018;55(6):5137-5153. PMID 28840449. Methylene blue clinical pharmacology + neuroprotective applications.

Internal KB references:

• the source digest for this article’s 5-part anatomy → intervention scaffold.
• the three-failures (insulin resistance + inflammation + ATP bankruptcy) framing that underpins the OHM mitochondrial-medicine editorial spine.
• the SS-31 / FDA-approval depth.
• the SS-31 vs MOTS-c peptide-layer detail.
• the structural-vs-functional framing for the peptide layer.
• MOTS-c clinical-protocol depth.
• NAD-precursor clinical sequencing for the matrix layer.

Cross-linked OHM wiki articles:

• MOTS-c · SS-31 (Elamipretide) · NAD+ · 5-Amino-1MQ · Glutathione · Methylene Blue — the alternative-electron-carrier mitochondrial adjunct (and the SSRI hard line you need to know about) · Epithalon · Humanin & ARA-290 — the endogenous protection cluster · Creatine — the foundational muscle + brain + metabolic adjunct (especially on a GLP-1)

Commercial layer

This is a framework article, not a per-SKU article. No specific Alyve product gets the headline CTA here — every per-peptide article it cross-links to carries the OHM-15 + bulk-stack CTA at its own bottom. The natural commercial flow from this article:

• Customer reads the framework, identifies the sub-system they want to target (matrix? biogenesis? cristae structure?), follows the cross-link to the per-peptide article, and lands on the Alyve CTA there.
• The bulk-stack discount (3 vials of any single peptide gets over 30% off retail with code OHM-15 at Alyve) applies once the customer commits to a multi-month protocol on a single peptide — most of the mitochondrial-cluster peptides (MOTS-c, NAD+) are 8-12 week cycles where buying 3 vials gives a full cycle’s supply with the bulk discount baked in.
• Adjunct supplements (CoQ10, NMN, urolithin A, phosphatidylcholine, omega-3) are widely available and not currently mapped to a specific OHM affiliate vendor. Recommend the standard third-party-tested brands (NSF-certified, Informed Sport-certified, or USP-verified where applicable).

If a customer’s question is “which mitochondrial peptide should I buy first?” — the framework answer is:

• If you’re sedentary, sleep-deprived, or otherwise haven’t built the foundation: none of them yet. Foundation first. (This is the OHM honest answer; everyone else’s marketing answer is “all of them, here’s a stack.”)
• If the foundation is in place and you want one entry point into the peptide layer: MOTS-c is the standard catalog entry point at the biogenesis layer — Alyve in-catalog, 8-week cycle, well-documented protocol (see MOTS-c for the per-vendor SKU and the cycling rotation).
• If you have suspected mitochondrial dysfunction or you’re running an active cycle of MOTS-c or NAD+ at intensity, the SS-31 cristae-stabilization layer becomes valuable, but it’s not in the Alyve launch catalog yet (roadmap candidate; see SS-31 (Elamipretide) for the current sourcing landscape).

---

This article is a framework piece. It exists so that the per-peptide deep dives in the rest of the KB can point upward at a single shared map of the system they each work on. If you found this article first, follow the cross-links into the per-peptide articles to find the lever for your specific situation. If you found a per-peptide article first, this is the upstream context that makes the peptide’s specific mechanism make sense.